Página 1 desde 173 resultados
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or
CROSS REFERENCE TO RELATED APPLICATIONS
This is a national stage application based on PCT/JP2012/076020, filed on Oct. 5, 2012, which claims priority to Japanese Patent Application Nos. 2011-225383, filed on Oct. 12, 2011, and 2012-081346, filed on Mar. 30, 2012. This application claims the priority
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 30, 2014, is named SEQLISTING75729.txt and is 628 bytes in size.
BACKGROUND
Fanconi
The present invention relates to a pharmaceutical composition for the treatment of the anemia of malignant tumors that comprises a therapeutically effective amount of human erythropoietin (hereinafter referred to as "human EPO") in a parenterally acceptable vehicle.
The term "human EPO" as used
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to pharmaceutical compositions containing as an effective ingredient, at least one substance selected from the polypeptides BUF-4 and BUF-5 (hereafter referred to as BUF-4 and BUF-5), more particularly, to
II. FIELD OF THE INVENTION
This invention relates to methods of using phenylacetic acid and its pharmaceutically acceptable derivatives as antitumor, and antiviral agents, and treatment of severe beta-chain hemoglobinopathies.
III. BACKGROUND OF THE INVENTION
Some of the most dreadful epidemics,
FIELD OF THE INVENTION
IL-6 antagonists, including anti-IL-6 antibodies and antigen-binding fragments thereof, may be used to reduce C-reactive protein ("CRP levels") and inflammation and in methods and compositions for the treatment and prevention of anemia, including anemia associated with
The sequence listing in the file named "67858o707001v3.txt" having a size of 342,545 bytes that was created Jun. 13, 2012 is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is an extension of Applicants' prior invention disclosed
I. FIELD OF THE INVENTION
This invention relates to methods of using phenylacetic acid and its pharmaceutically acceptable derivatives to treat and prevent pathologies and to modulate cellular activities. In particular, this invention relates to A) phenylacetate and its derivatives in cancer
I. FIELD OF THE INVENTION
This invention relates to methods of using phenylacetic acid and its pharmaceutically acceptable derivatives to treat and prevent pathologies and to modulate cellular activities. In particular, this invention relates to A) phenylacetate and its derivatives in cancer
BACKGROUND
1. Field of the Invention
The field of the invention is generally related to methods of treating anemia with an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF).
2. Description of Related Art
The production of red blood cells in mammals,
BACKGROUND
The present invention pertains to compositions and methods for plasmid-mediated supplementation. The present invention pertains to compositions and methods that are useful for retarding the growth rate of abnormal cells, tumor progression reduction, prevention of kidney failure, reduction
FIELD OF THE INVENTION
The present invention is directed to a new use for Erythropoetin ("EPO"), such as EPO alpha, for treating hepatitis C and/or anemia caused by hepatitis C treatment. Accordingly, the invention involves using EPO with hepatitis C treatment, such as Ribavirin ("RBV") and/or
FIELD OF THE INVENTION
The present invention is directed to a new use for Erythropoetin ("EPO"), such as EPO alpha, for treating hepatitis C and/or anemia caused by hepatitis C treatment. Accordingly, the invention involves using EPO with hepatitis C treatment, such as Ribavirin ("RBV") and/or
The present invention relates to novel proteins and/or polypeptides of the Chicken Anemia Virus. Besides, it relates to vaccines and compositions for preventing or treating virus infections in poultry, in particular infections with the Chicken Anemia Virus (CAV).
In particular, the invention relates